Menu
Menu
Colorectal cancer (CRC) is a critical health concern in Singapore and the Philippines. In Singapore, it’s the most common cancer overall and the second leading cause of cancer-related deaths.
Alarmingly, only about 40% of CRC cases are diagnosed at early stages, and just 38% of Singapore residents aged 50-74 undergo recommended CRC screening. Timely screening is crucial for early detection, which significantly improves treatment outcomes and survival rates. With early-stage CRC having over 90% 5-year survival rates compared to less than 10% for late-stage diagnoses, the importance of regular screening cannot be overstated.
ColonAiQ® offers a new, more accessible way to prioritize your health through early CRC detection.
Higher Sensitivity: ColonAiQ® demonstrates superior sensitivity compared to FIT (Fecal Immunochemical Test): (5) (6)
Patient Preference: Most patients prefer blood tests over stool-based tests, potentially increasing screening compliance. (4)
Improved Early Detection: ColonAiQ® significantly increases detection rates for precancerous adenomas and early-stage CRC compared to existing molecular screening tests. (6)
ColonAiQ® is a cutting-edge, multi-locus blood-based assay that targets circulating tumor DNA methylation. This innovative technology offers unparalleled success in non-invasive early detection of both colorectal cancer (CRC) and advanced adenoma (AA). (6)
01. https://gco.iarc.who.int/media/globocan/factsheets/populations/702-singapore-fact-sheet.pdf
04. https://doi.org/10.1016/j.ctarc.2016.12.004
Liles, E. G., Coronado, G. D., Perrin, N., Harte, A. H., Nungesser, R., Quigley, N., Potter, N. T., Weiss, G., Koenig, T., & de Vos, T. (2017). Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: A randomized trial. Cancer Treatment and Research Communications, 10, 18-23. https://doi.org/10.1016/j.ctarc.2016.12.004
05. https://doi.org/10.1097/JS9.0000000000000260
Song, D., Wang, F., Ju, Y., He, Q., Sun, T., Deng, W., Ding, R., Zhang, C., Xu, Q., Qi, C., & Bao, J. (2023). Application and development of noninvasive biomarkers for colorectal cancer screening: a systematic review. International Journal of Surgery, 109(4), 925–935. https://doi.org/10.1097/JS9.0000000000000260
06. https://doi.org/10.1053/j.gastro.2021.08.054
Cai, G., Cai, M., Feng, Z., Liu, R., Liang, L., & Zhou, P. (2021). A Multilocus Blood-Based Assay Targeting Circulating Tumor DNA Methylation Enables Early Detection and Early Relapse Prediction of Colorectal Cancer. Gastroenterology, 161(6), 2053-2056.e2. https://doi.org/10.1053/j.gastro.2021.08.054
07. https://doi.org/10.1016/j.ctarc.2016.12.004
Liles, E. G., Coronado, G. D., Perrin, N., Harte, A. H., Nungesser, R., Quigley, N., Potter, N. T., Weiss, G., Koenig, T., & de Vos, T. (2017). Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: A randomized trial. Cancer Treatment and Research Communications, 10, 18-23. https://doi.org/10.1016/j.ctarc.2016.12.004
About Colonoscopy
https://www.gastrojournal.org/article/S0016-5085(21)03031-6/fulltext
Saver’s Med Pte Ltd is the exclusive distributor for Singlera’s ColonAiQ® in Singapore and the Philippines.
ColonAiQ is currently undergoing review by the Health Sciences Authority (HSA) for registration as a medical device in Singapore and the Philippines.
Sign up for our waitlist to be among the first to be notified when ColonAiQ becomes available!